MYGN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MY

Mkt Cap

$380.2M

Volume

1.14M

Next Earnings

November 2nd

Loading chart

MY

MYGNMyriad Genetics Inc

MYGN

Pay with—

Available Balance0.00

MY

Mkt Cap

$416.1M

Volume

1.14M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product SegmentsThe global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.GlobeNewswire Inc. · Sep 24, 2026

Myriad Genetics Appoints Vishal Sikri Executive Vice President - CommercialMyriad Genetics announced the promotion of Vishal Sikri to Executive Vice President - Commercial effective September 16, 2026, replacing departing Chief Commercial Officer Brian Donnelly. Sikri, who previously served as SVP of Product, brings molecular diagnostics and oncology expertise. The company reaffirmed its full-year 2026 financial guidance.GlobeNewswire Inc. · Sep 16, 2026

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.GlobeNewswire Inc. · Aug 7, 2026

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudLaw firm Kirby McInerney LLP is investigating Myriad Genetics for potential securities fraud following the company's July 30, 2026 earnings report. Myriad reported an 11% year-over-year revenue decline to $190.7 million, reduced full-year guidance, and an $11 million revenue adjustment. Hereditary cancer testing revenue fell 13% despite volume growth, attributed to lower reimbursement and unfavorable estimate changes. Management acknowledged delayed engagement with payers regarding authorization and denial issues. The stock declined 47% to $2.86 on July 31, 2026.GlobeNewswire Inc. · Aug 6, 2026

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS InsiderThe global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.GlobeNewswire Inc. · Jun 19, 2026

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her LifeMyriad Genetics announced a partnership with Netflix actress Jackie Tohn to promote awareness about hereditary cancer testing through the MyRisk® Hereditary Cancer Test. Tohn discovered she carried a BRCA1 gene variant and underwent preventive measures after learning she had an 85% risk of breast cancer and 65% risk of ovarian cancer. The MyRisk test evaluates 63 genes across 11 cancer types and is available through healthcare providers or virtual care.GlobeNewswire Inc. · May 15, 2026

Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsightThe cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.GlobeNewswire Inc. · May 14, 2026

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026Myriad Genetics announced the advancement of its Precise MRD product toward a March 2026 launch, supported by new breast and colorectal cancer study data demonstrating ultrasensitive ctDNA detection. The company also released select preliminary fourth quarter and full year 2025 financial results and provided full year 2026 financial guidance.GlobeNewswire Inc. · Feb 16, 2026

Decoding Our DNA: The Human Impact Behind SNP Genotyping’s USD 19.48 Billion Growth by 2034The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and pharmaceutical companies are the primary end users. Key drivers include personalized medicine adoption, technological advancements, and increased genomics research investments.GlobeNewswire Inc. · Feb 13, 2026

Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.GlobeNewswire Inc. · Jan 30, 2026

to start trading

MY

MYGNMyriad Genetics Inc

MYGN

Pay with—

Available Balance0.00

Your PositionYou don't own any MYGN yet.

Related Tickers

Earnings